title: Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries.
abstract: Prevention of ovarian cancer is the best approach for reducing the impact of this deadly disease. The laying hen is a robust model of spontaneous ovarian cancer that recapitulates the human disease. Dietary intervention with flaxseed, the richest vegetable source of omega-3 fatty acids (OM-3FAs) and phytoestrogen lignans, demonstrate the potential for effective prevention and amelioration of ovarian cancer by targeting inflammatory prostaglandin pathways. Prostaglandin E2 (PGE2) is the most pro-inflammatory ecoisanoid and one of the downstream products of two isoforms of cyclooxygenase (COX) enzymes: COX-1 and COX-2. Our objective was to investigate the effect of flaxseed supplementation for one year on ovarian cancer and correlate its effects to expression of COX enzymes and concentrations of prostaglandins. White Leghorn hens were fed 10% flaxseed-enriched or standard diet for one year. The severity of ovarian cancer was determined by gross pathology and histology. COX-1 and COX-2 localization and protein and mRNA expression and PGE2 and PGE3 concentrations in ovaries were measured by IHC, western blot, quantitative real-time PCR and LC-MS-MS, respectively. The results demonstrated a significant reduction in late stage ovarian tumors in the flaxseed-fed hens compared with the control diet-fed hens. In correlation with decreased ovarian cancer severity, concentrations of PGE2 and expression of COX-2 were diminished in ovaries of flaxseed-fed hens. PGE3 concentrations were below the level of detection. The results demonstrated that in normal ovaries, COX-1 was localized to the granulosa cell layer surrounding the follicles and ovarian surface epithelium (OSE) whereas COX-2 protein was localized to the granulosa cell layer in the follicle. Extensive COX-1 and COX-2 protein expression was found throughout the ovarian carcinoma. Our findings suggest that the flaxseed-mediated reduction in the severity of ovarian cancer in hens is correlated to the reduction in PGE2 in the ovaries of flaxseed-fed hens. These findings may provide the basis for clinical trials of dietary intervention targeting prostaglandin biosynthesis for the prevention and treatment of ovarian cancer.
authors: Department of Physiology, Southern Illinois University at Carbondale, School of Medicine, Carbondale, IL, USA.
authors: Erfan
authors: E
authors: Eilati
authors: Karen
authors: K
authors: Hales
authors: Yan
authors: Y
authors: Zhuge
authors: Kristine
authors: K
authors: Ansenberger Fricano
authors: Rui
authors: R
authors: Yu
authors: Richard B
authors: RB
authors: van Breemen
authors: Dale Buchanan
authors: DB
authors: Hales
mesh_terms: D000821:Animal Feed; D000818:Animals; D030161:Avian Proteins / Q000235:genetics / Q000378:metabolism; D002645:Chickens; D051545:Cyclooxygenase 1 / Q000235:genetics / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D004032:Diet; D019587:Dietary Supplements; D015232:Dinoprostone / Q000096:biosynthesis*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism; D005260:Female; D019597:Flax; D015870:Gene Expression; D006801:Humans; D010051:Ovarian Neoplasms / Q000517:prevention & control / Q000662:veterinary*; D010053:Ovary / Q000378:metabolism*; D010060:Ovulation; D011201:Poultry Diseases / Q000517:prevention & control*; D058309:Receptors, Prostaglandin E, EP4 Subtype / Q000235:genetics
chemical_list: D030161:Avian Proteins; D015525:Fatty Acids, Omega-3; D058309:Receptors, Prostaglandin E, EP4 Subtype; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone
keywords: Cyclooxygenases; Flaxseed; Laying hen; Ovarian cancer; Prostaglandin E(2)
references: J Pharmacol Exp Ther. 2011 Nov;339(2):716-25
references: 21865441
references: Mol Carcinog. 2004 Jul;40(3):180-8
references: 15224350
references: Clin Cancer Res. 2006 Aug 1;12(15):4662-70
references: 16899616
references: Cancer Res. 2005 May 1;65(9):3735-44
references: 15867369
references: Prostaglandins. 1985 May;29(5):665-72
references: 3859890
references: Int J Cancer. 2005 Nov 10;117(3):340-8
references: 15900589
references: Gynecol Oncol. 2013 Sep;130(3):620-8
references: 23707669
references: Curr Opin Cell Biol. 2005 Apr;17(2):174-82
references: 15780594
references: J Vet Intern Med. 2007 Sep-Oct;21(5):1048-55
references: 17939563
references: Mol Endocrinol. 1991 Sep;5(9):1269-79
references: 1722869
references: Gynecol Oncol. 2009 Jan;112(1):171-8
references: 18973935
references: Oncogene. 1999 Dec 20;18(55):7908-16
references: 10630643
references: Cancer Res. 2010 Feb 15;70(4):1606-15
references: 20145136
references: Nat Rev Cancer. 2001 Oct;1(1):11-21
references: 11900248
references: J Biol Chem. 2002 Aug 2;277(31):27613-21
references: 12000750
references: J AOAC Int. 2013 Jan-Feb;96(1):67-76
references: 23513960
references: Annu Rev Physiol. 2002;64:69-92
references: 11826264
references: Endocrine. 2008 Jun;33(3):235-44
references: 18498063
references: Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36
references: 21864702
references: J Biol Chem. 2004 Nov 5;279(45):46700-5
references: 15347673
references: J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73
references: 12009392
references: Int J Gynecol Cancer. 2009 May;19(4):531-9
references: 19509547
references: Endocrinology. 1992 Nov;131(5):2165-72
references: 1425417
references: Cancer Res. 2006 Mar 15;66(6):3106-13
references: 16540660
references: Gynecol Oncol. 2010 May;117(2):341-7
references: 20153884
references: Nucleic Acids Res. 2012 Aug;40(14):6863-72
references: 22544606
references: Cancer Res. 2006 Mar 15;66(6):2923-7
references: 16540639
references: Pancreas. 2008 May;36(4):353-62
references: 18437081
references: J Lipid Res. 2005 Jun;46(6):1278-84
references: 15772428
references: Genes Dev. 1999 Jun 15;13(12):1561-74
references: 10385625
references: J Pharm Biomed Anal. 2011 Jan 5;54(1):230-5
references: 20817448
references: Trends Pharmacol Sci. 2003 Feb;24(2):96-102
references: 12559775
references: Nat Rev Cancer. 2013 Jun;13(6):432-6
references: 23676850
references: J Clin Oncol. 2008 Feb 20;26(6):995-1005
references: 18195328
references: Poult Sci. 1996 Oct;75(10):1221-6
references: 8893298
references: J Clin Immunol. 1983 Oct;3(4):295-315
references: 6140268
references: Nutr J. 2004 Oct 20;3:19
references: 15496224
references: Cancer Res. 2005 Sep 1;65(17):8022-7
references: 16140976
references: Gynecol Oncol. 2001 Jun;81(3):373-9
references: 11371125
references: Med Hypotheses. 2012 Jan;78(1):45-57
references: 22001128
references: FASEB J. 2011 Jul;25(7):2408-17
references: 21450910
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: J Nutr. 2002 Nov;132(11 Suppl):3508S-3512S
references: 12421878
references: Front Biosci. 1997 Oct 01;2:d482-500
references: 9300941
references: Gynecol Oncol. 2006 Nov;103(2):673-8
references: 16797680
references: Prostaglandins Leukot Essent Fatty Acids. 2012 Dec;87(6):177-84
references: 23089186